Product
ATI-2173
2 clinical trials
4 indications
Indication
Hepatitis BIndication
ChronicIndication
Hepatitis DIndication
Chronic Hepatitis BClinical trial
A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus CoinfectionStatus: Terminated, Estimated PCD: 2022-09-01
Clinical trial
A Phase 1, Open-Label, 3-Cohort, Parallel, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose ATI-2173 50 mg in Healthy Japanese, Chinese, and Non-Asian SubjectsStatus: Terminated, Estimated PCD: 2022-08-22